COMP <GO>
KEQU vs UNH // GROSS PROFIT MARGIN
Kewaunee Scientific Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: KEQU 9
— UNH 4
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $33.51 (-3.48%) • MKT CAP: $97.0M
gross-margins
28.50%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
gross-margins
88.57%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KEQU VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KEQU | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 28.50% | 88.57% | -60.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.70% | 11.47% | +5.23 | KEQU | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.3x | 16.4x | -10.15 | KEQU | /valuation <GO> |
| Free Cash Flow Yield | 19.20% | 6.48% | +12.72 | KEQU | /fcf-yield <GO> |
| Operating Margin | 5.90% | 4.82% | +1.08 | KEQU | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 3.14% | +0.26 | KEQU | /net-margins <GO> |
| Revenue Growth (YoY) | 17.30% | 6.46% | +10.84 | KEQU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.37 | 3.12 | +0.25 | KEQU | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | KEQU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 59.2 | -9.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 17.7x | -9.24 | KEQU | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $97.0M | $368.83B | -$368.73B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KEQU REV | UNH REV | KEQU GROSS % | UNH GROSS % | KEQU FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $282.0M | $447.57B | 28.5% | 88.7% | $18.6M | $16.07B |
| FY 2024 | $240.5M | $400.28B | 28.6% | 88.3% | $14.8M | $20.70B |
| FY 2023 | $203.8M | $371.62B | — | 89.6% | $19.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KEQU // BETA —
UNH // BETA 0.33